Page last updated: 2024-12-08

globotriose

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

alpha-D-Galp-(1->4)-alpha-D-Galp-(1->4)-beta-D-Glcp : A trisaccharide consisting of two alpha-D-galactose residues and a beta-D-glucose at the reducing end in a linear sequence and joined by (1->4) linkages. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID45480593
CHEBI ID59481
SCHEMBL ID233179
MeSH IDM0293002

Synonyms (12)

Synonym
66580-68-5
globotriose
CHEBI:59481
alpha-d-galactopyranosyl-(1->4)-alpha-d-galactopyranosyl-(1->4)-beta-d-glucopyranose
alpha-d-galactosyl-(1->4)-alpha-d-galactosyl-(1->4)-beta-d-glucose
alpha-d-gal-(1->4)-alpha-d-gal-(1->4)-beta-d-glc
galalpha1-4galalpha1-4glcbeta
alpha-d-galp-(1->4)-alpha-d-galp-(1->4)-beta-d-glcp
alpha-gal-(1->4)-alpha-gal-(1->4)-beta-glc
SCHEMBL233179
Q27126734
(2r,3r,4s,5r,6r)-2-{[(2r,3r,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-{[(2r,3s,4r,5r,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy}oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
trisaccharide
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (43)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (13.95)18.2507
2000's16 (37.21)29.6817
2010's17 (39.53)24.3611
2020's4 (9.30)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (4.65%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other41 (95.35%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]